-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
EFdA-TP-tetraammonium
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/efda-tp-tetraammonium.gif)
| Category | Human immunodeficiency Virus (HIV) |
| Description | EFdA-TP tetraammonium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetraammonium inhibits RT- catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits HIV-1 RT with multiple mechanisms |
Product Information
| Synonyms | EFdA-TP tetraammonium |
| Molecular Weight | 601.32 |
| Molecular Formula | C12H27FN9O12P3 |
| Purity | 98.03% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Off-white to light yellow (Solid) |
| Storage | -20°C, sealed storage, away from moisture and light * In solvent : -80°C 6 months; -20°C 1 month (sealed storage, away from moisture and light) |
| In Vitro | EFdA-TP tetraammonium (0.05-10 μM; for 15 min) inhibits RT-catalyzed DNA synthesis as an ICT or DCT. EFdA-TP tetraammonium can block RT as a translocation-defective RT inhibitor that dramatically slows DNA synthesis, acting as a de facto immediate chain terminator. EFdA-TP tetraammonium can function as a delayed chain terminator, allowing incorporation of an additional dNTP before blocking DNA synthesis. |
| Target | Reverse Transcriptase; DNA/RNA Synthesis; HIV |
